*
*Neuroblastoma** (* * N . B . * *)|432328008
is
the most common extracranial solid cancer|4757001|72906007|303232006|35702001|363346000|4757001|72906007|303232006|35702001|372087000|4757001|72906007|303232006|78910004|363346000|4757001|72906007|303232006|78910004|372087000|4757001|72906007|303232006|421378002|363346000|4757001|72906007|303232006|421378002|372087000
in childhood|68433009
and
the most common cancer|4757001|72906007|363346000|4757001|72906007|372087000
in infancy,|3658006
with an annual incidence|53281000
of about six hundred and fifty cases|422218008|398241000|422218008|413769002
per year|258707000|259039008
in the U.S.,|223688001
[1]|260305007
and
a hundred cases|398241000|413769002
per year|258707000|259039008
in the U.K.

Nearly half
of neuroblastoma cases|432328008|398241000|432328008|413769002|398241000|413769002
occur|272120004
in children|410601007|160499008
younger|84422007
than two years.|420797005|258707000

It
is
a neuroendocrine tumor,|255046005
arising|68727004
from any neural crest element|361462002|57795002
of the sympathetic nervous system (S.N.S.).|68365008|362484004

It most frequently|4757001|70232002
originates
in one|421379005
of the adrenal glands,|23451007
but
can
also
develop
in nerve tissues|91728009
in the neck,|45048000|302550007
chest,|261179002
abdomen,|277112006|52731004|302553009
or
pelvis.|277113001|21844003|229765004

Neuroblastoma|432328008
is
one|421379005
of the few human malignancies|57176003|278412004|363346000
known|36692007
to
demonstrate
spontaneous regression|5054005|48386003
from an undifferentiated state|263918006|398070004
to a completely benign cellular appearance.|30807003|4421005|386548000|30807003|4421005|255412001

It
is
a disease|64572001
exhibiting
extreme heterogeneity,|12565001
and
is
stratified|44308007
into three risk categories|421291004|30207005
:
low, intermediate,|62482003|11896004|371880002|11896004
and
high risk.|15508007

Low-risk disease|62482003|30207005|64572001|371880002|30207005|64572001
is
most common|4757001|72906007
in infants|418119000
and
good outcomes|20572008|394617004
are
common|72906007
with observation only|103705002
or
surgery,|83578000
whereas
high-risk disease|15508007|64572001
is
difficult to|52925006
treat|395077000
successfully even
with the most intensive multi-modal therapies available.[5]|4757001|260396001|276239002|103328004

Esthesioneuroblastoma,|422886007
also
known|36692007
as olfactory neuroblastoma,|422886007
is
believed to
arise|68727004
from the olfactory epithelium|37623003
and
its classification|73504009
remains
controversial.

However,
since
it
is
not
a sympathetic nervous system malignancy|68365008|363346000|68365008|372087000|362484004|363346000|362484004|372087000
it
is
a distinct clinical entity|58147004
and
is
not to
be
confused|286933003
with neuroblastoma.[6][7]|432328008

The first symptoms|255216001|232714002
of neuroblastoma|432328008
are
often|70232002
vague|25615006
making diagnosis|439401001
difficult.|52925006

Fatigue,|84229001
loss
of appetite,|33911006
fever,|386661006
and
joint pain|57676002
are
common.|72906007

Symptoms
depend
on primary tumor locations|63161005|108369006|246267002|261424001|108369006|246267002
and
metastases|128462008
if
present|52101004|246105001
:
[8]

Neuroblastoma often|432328008|70232002|70232002
spreads|410677005
to other parts|74964007|260726005
of the body|279495008|123037004
before any symptoms
are
apparent
and
50
to 60%
of all neuroblastoma cases|432328008|398241000|432328008|413769002|398241000|413769002
present|52101004|246105001
with metastases.[9]|128462008

The most common location|4757001|72906007|246267002
for neuroblastoma to|432328008
originate
(i.e.|42146005|22971001

the primary tumor|63161005|108369006|261424001|108369006
)
is
on the adrenal glands.|23451007

This
occurs|272120004
in 40%|259031006
of localized tumors|255471002|108369006
and
in 60%
of cases|398241000|413769002
of widespread disease.|85333001|64572001

Neuroblastoma|432328008
can
also
develop
anywhere
along the sympathetic nervous system chain|68365008|46666003|362484004|46666003
from the neck|45048000|302550007
to the pelvis.|277113001|21844003|229765004

Frequencies|272123002
in different locations|263735002|246267002
include|55919000
:
neck|45048000|302550007
(1%|260305007
)
,
chest|261179002
(19%
)
,
abdomen|277112006|52731004|302553009
(30% non-adrenal|23451007
)
,
or
pelvis|277113001|21844003|229765004
(1%|260305007
).

In rare cases,|84638005|398241000|84638005|413769002|103356009|398241000|103356009|413769002
no primary tumor|63161005|108369006|261424001|108369006
can
be
discerned.[10]

Rare|84638005|103356009
but
characteristic presentations|246105001
include|55919000
transverse myelopathy|62824007|127035006|62824007|48522003|243899009|127035006|243899009|48522003
(tumor spinal cord compression,|108369006|71286001
5%|264706000|264605009
of cases|398241000|413769002
)
,
treatment-resistant diarrhea|276239002|30714006|398032003|416118004|30714006|398032003
(tumor vasoactive intestinal peptide secretion,|108369006|11652002|46242002
4%|260308009
of cases|398241000|413769002
)
,
Horner's syndrome|192915005|271730003
(cervical tumor,|123841004
2.4%|260306008
of cases|398241000|413769002
)
,
opsoclonus myoclonus syndrome[11]|230350000
and
ataxia|20262006
(suspected paraneoplastic cause,|134198009|415684004|134198009
1.3%|260305007
of cases|398241000|413769002
)
,
and
hypertension|38341003
(catecholamine secretion|34582008|46242002
or
renal artery compression,|2841007|71173004|2841007|263720003|181339005|71173004|181339005|263720003
1.3%|260305007
of cases|398241000|413769002
).[12]

The etiology|134198009
of neuroblastoma|432328008
is
not well understood.|20572008|66216009

Certain cases however|17162000|398241000|17162000|413769002
do
run in families|418060005|35359004|282476009|35359004
and
have
been
linked
to genetics.

Familial neuroblastoma|35359004|432328008|35359004|255401001|432328008|255401001
is
caused|23981006|134198009
by a very rare germline mutation|260358002|84638005|55446002|260358002|103356009|55446002
in the anaplastic lymphoma kinase (ALK) gene.[13]|304257007|67271001

N-myc amplification|258310009
is
a common finding|72906007|404684003|72906007
in these tumours.|108369006

The degree|258395000|246173007
of amplification
shows
a bimodal distribution -|255464007
either
3-|260313008
to 10-fold,|26310004
or
100-
to 300-fold.|26310004

The presence|386397008
of this mutation|55446002
is
highly|75540009
correlated
to advanced stages|86005002|261612004
of disease.[14]|64572001

LMO1 gene|67271001
has
been
found|404684003
to
be
a contributor
to neuroblastoma,|432328008
increasing|260369004
the risk|30207005
of developing
an aggressive form|61372001|246176004|246176004
of the cancer.[15]|363346000|372087000

Neuroblastoma|432328008
has
been
linked
to problems|55607006
with the gene NBPF10|67271001
in relation to copy-number variants|410680006|40885006|410681005|40885006
which
cause|23981006|134198009
the 1q21.1 deletion syndrome
and
1q21.1 duplication syndrome.[16]|89049001

Several risk factors|261028005|80943009
have
been
proposed
and
are
the subject
of ongoing research.|255238004

Due to characteristic early onset many studies|264499004|77374008|110465008|264499004|77374008|224699009
have
focused|87017008|363702006
on parental factors|40683002
around conception|13693004
and
during gestation.|289908002

Factors
investigated|116698004
have
included occupation|55919000|14679004
(i.e.|42146005|22971001

exposure|71677004|24932003
to chemicals|441900009
in specific industries|69658003
)
,
smoking|365981007
,
alcohol consumption,|160573003
use|277889008|419385000
of medicinal drugs|410942007
during pregnancy|289908002
and
birth factors|3950001
;
however,
results|394617004
have
been
inconclusive.[17]|419984006

Other studies|74964007|110465008|74964007|224699009
have
examined possible links|64049009|371930009|64049009|60022001
with atopy|115665000
and
exposure|71677004|24932003
to infection early in life,[18]|264499004|224130005
use|277889008|419385000
of hormones|87568004
and
fertility drugs,|125582005
[19]
and
maternal use|72705000|277889008|72705000|419385000
of hair dye.[20][21]|412145001

The diagnosis|439401001
is
usually
confirmed|59156000
by a surgical pathologist,|83578000|61207006
taking|419652001
into
account
the clinical presentation,|58147004|246105001
microscopic findings,|84496004|404684003|84496004
and
other laboratory tests.|74964007|269814003

In about 90%|264705001|264703008
of cases|398241000|413769002
of neuroblastoma,|432328008
elevated levels|75540009|258395000
of catecholamines|34582008
or
their metabolites
are
found|404684003
in the urine|78014005
or
blood.|87612001|119273009

Catecholamines|34582008
and
their metabolites
include|55919000
dopamine,|412383006|32779004
homovanillic acid (HVA),|84926003|67274009
and/or
vanillylmandelic acid (VMA).[22]|81810001

Another way to
detect|260373001
neuroblastoma|432328008
is
the mIBG scan|395786000|373205008|395786000
(meta-iodobenzylguanidine|395786000
)
,
which
is
taken|419652001
up
by 90|264705001|264703008
to 95%
of all neuroblastomas,|432328008
often|70232002
termed "mIBG-avid."[23]|395786000|264657009
The mechanism|257544000
is
that mIBG|395786000
is
taken|419652001
up
by sympathetic neurons,|47220008
and
is
a functioning analog|246464006
of the neurotransmitter norepinephrine.|35069000|45555007

When
it
is
radio-ionated|360004001
with I-131|404836005
or
I-123|21572004
(radioactive iodine isotopes,|89457008|42146005|89457008|44588005|67719005
it
is
a very good radiopharmaceutical|260358002|20572008|349358000
for diagnosis|439401001
and
monitoring|302805002
of response
to treatment|276239002|416118004
for this disease.|64572001

With a half-life|224130005
of 13 hours,|258702006
I-123|21572004
is
the preferred isotope|225773000|33638001
for imaging sensitivity|363679005|35209006|363679005|365705006|278395004|35209006|278395004|365705006
and
quality.|263496004

I-131|404836005
has
a half-life|224130005
of 8 days|258703001
and
at higher doses|261829003
is
an effective therapy|255403003|276239002|254648000|276239002
as targeted radiation|30821001|82107009|108290001
against relapsed|255318003
and
refractory neuroblastoma.[24]|20646008|432328008|20646008

On microscopy,|117259009
the tumor cells|252987004
are
typically
described
as small, round|255507004|42700002
and
blue,|405738005
and
rosette patterns|12170000|272135003
(Homer-Wright pseudo-rosettes|25177008|373682001|64100000|12170000
)
may
be
seen.

Homer-Wright pseudorosettes,|25177008|373682001
are
tumor cells|252987004
around neuropil,|67146008
not to
be
confused|286933003
with true rosettes|31874001|12170000
(Flexner-Wintersteiner
)
[25]
which
are
tumor cells|252987004
around a blood vessel often|59820001|70232002|361097006|70232002
seen
in retinoblastomas.|370967009

They
are
also distinct
from the pseudorosettes
of an ependymoma|443643007
which
consist
of tumor cells|252987004
with glial fibrillary acidic protein (GFAP)?positive processes|24675006|258758003|415178003|24675006|10828004|415178003
tapering|257935006
off
toward a blood vessel|59820001|361097006
(thus
a combination|89780004
of the two|420797005
).

A variety
of immunohistochemical stains|397165007|127790008
are
used|394850002
by pathologists to|61207006
distinguish
neuroblastomas|432328008
from histological|67151002
mimics
,
such as rhabdomyosarcoma,|302847003
Ewing's sarcoma,|76909002
lymphoma|118600007
and
Wilms' tumor.|302849000

Neuroblastoma|432328008
is
one|421379005
of the peripheral neuroblastic tumors (pNTs)|14414005|108369006
that
have
similar origins|255395001
and
show
a wide pattern|90522003|272135003
of differentiation ranging
from benign ganglioneuroma|30807003|53801007
to stroma-rich ganglioneuroblastoma|224166006|69515008
with neuroblastic cells|4421005
intermixed
or
in nodules,|27925004|279365004
to highly malignant neuroblastoma.|75540009|21594007|432328008|75540009|21594007

This distinction
in the pre-treatment tumor pathology|236874000|276239002|108369006|394595002|236874000|416118004|108369006|394595002|272113006|276239002|108369006|394595002|272113006|416118004|108369006|394595002
is
an important prognostic factor,
along
with age|424144002
and
mitosis-karyorrhexis index (MKI).|27350008|34064004

This pathology classification system|394595002|73504009
describes
"favorable"
and
"unfavorable" tumors|108369006
by the International Neuroblastoma Pathology Committee|432328008|394595002|394595002
(INPC,
also called Shimada system|246333005
)
which
was
established|263748003|385645004
in 1999
and
revised|261560009
in 2003.[28]

The "International Neuroblastoma Staging System" (INSS)|254363005
established|263748003|385645004
in 1986
and
revised|261560009
in 1988 stratifies neuroblastoma|44308007|432328008|44308007
according to its anatomical presence|36298004|386397008
at diagnosis|439401001
:
[29][30][31]|264664006

Although
international agreement
on staging|72589006
(INSS|254363005
)
has
been
used|394850002
,
the need|410525008|103325001
for an international consensus
on risk assignment|30207005
has
also
been
recognized
in order to
compare
similar cohorts
in results|394617004
of studies.|110465008|224699009

Beginning|255395001
in 2005,
representatives
of the major pediatric oncology cooperative groups|255603008|418002000|261586004|255603008|418002000|160481000
have
met|229057006
to
review
data
for 8,800 neuroblastoma patients|432328008|116154003|116154003
treated|28995006
in Europe,|223502009
Japan,|223583001
USA,|223688001
Canada,|223686002
and
Australia|223621005
between 1990
and
2002.

This task force|285653008
has
proposed
the International Neuroblastoma Risk Group (INRG) classification system.|432328008|30207005|261586004|73504009|432328008|30207005|160481000|73504009|432328008|30207005|389109008|73504009|30207005|261586004|73504009|30207005|160481000|73504009|30207005|389109008|73504009

Retrospective studies|110465008|224699009
revealed|263857004
the high survival rate|75540009|371879000
of 12-18 month old age group,|258706009|105436006|261586004|258706009|105436006|160481000|258706009|105436006|389109008|258706009|32864002|261586004|258706009|32864002|160481000|258706009|32864002|389109008|259036001|105436006|261586004|259036001|105436006|160481000|259036001|105436006|389109008|259036001|32864002|261586004|259036001|32864002|160481000|259036001|32864002|389109008
previously
categorized
as high-risk,|15508007
and
prompted
the decision to
reclassify|76561005
12-18 month old children|258706009|70753007|410601007|258706009|70753007|160499008|259036001|70753007|410601007|259036001|70753007|160499008
without N-_myc_|258310009
(also commonly
referred|439980006
to
as
MYCN amplification
to intermediate risk category.[32]|11896004|30207005

The new INRG risk assignment|7147002|30207005
will
classify|73504009
neuroblastoma|432328008
at diagnosis|439401001
based|418836005
on a new International Neuroblastoma Risk Group Staging System (INRGSS)|7147002|254363005|30207005|261586004|7147002|254363005|30207005|160481000|7147002|254363005|30207005|389109008
:

The new risk stratification|7147002|30207005
will
be
based|418836005
on the new INRGSS staging system,|7147002|246231009
age|424144002
(
dichotomized
at 18 months|258706009
)
,
tumor grade,|108369006|258349007|108369006|371469007
N-myc amplification,|258310009
unbalanced 11q aberration,|260980007
and
ploidy|88183001
into four pre-treatment risk groups|421534005|236874000|276239002|30207005|261586004|421534005|236874000|276239002|30207005|160481000|421534005|236874000|416118004|30207005|261586004|421534005|236874000|416118004|30207005|160481000|421534005|272113006|276239002|30207005|261586004|421534005|272113006|276239002|30207005|160481000|421534005|272113006|416118004|30207005|261586004|421534005|272113006|416118004|30207005|160481000
:
very low, low, intermediate,|260362008|11896004
and
high risk.[33][34]|15508007|264667004

Urine catecholamine level|309618006
can
be
elevated|75540009
in pre-clinical neuroblastoma.|236874000|58147004|432328008|236874000|58147004|272113006|58147004|432328008|272113006|58147004

Screening|20135006
asymptomatic infants|84387000|418119000
at three weeks,|421291004|258705008
six months,|422218008|258706009
and
one year|421379005|258707000|421379005|259039008
has
been
performed|398166005
in Japan,|223583001
Canada,|223686002
Austria|223635007
and
Germany|223637004
since
the 1980s.

Japan|223583001
began|255395001
screening six-month olds|20135006|422218008|258706009|70753007|20135006|422218008|259036001|70753007
for neuroblastoma|432328008
via analysis|272389005
of the levels|258395000
of homovanillic acid|84926003|67274009
and
vanilmandelic acid|81810001
in 1984.

Screening|20135006
was
halted
in 2004
after studies|110465008|224699009
in Canada|223686002
and
Germany|223637004
showed
no reduction|58294000|260400001|289928003
in deaths|419620001|268923008
due to neuroblastoma,|432328008
but
rather
caused|23981006|134198009
an increase|260366006
in diagnoses|439401001
that
would
have
disappeared
without treatment,|276239002|416118004
subjecting
those infants|418119000
to unnecessary surgery|83578000
and
chemotherapy.|416608005|367336001

[39]

When
the lesion
is
localized,|255471002
it
is
generally curable.

However,
long-term survival
for children|410601007|160499008
with advanced disease|86005002|64572001
older|70753007
than 18 months|258706009
of age|424144002
is
poor|11403006|255351007
despite aggressive multimodal therapy|61372001|276239002|276239002
(intensive chemotherapy,|416608005|367336001
surgery,|83578000
radiation therapy,|108290001
stem cell transplant,|418318001|263903005|418318001|24486003|419758009|263903005|419758009|24486003
differentiation agent isotretinoin also|260872001|429464002
called
13-_cis_-retinoic acid,|429464002
and
frequently immunotherapy[40]|70232002|76334006|259031006
with anti-GD2 monoclonal antibody therapy.|49616005|276239002

Biologic|12893009
and
genetic characteristics|3950001|255395001
have
been
identified|7882003
,
which,
when
added
to classic clinical staging,|255301002|260998006|255333006|260998006
has
allowed patient assignment to risk groups|116154003|30207005|261586004|116154003|30207005|160481000
for planning treatment intensity.|312011006|276239002|103370009|312011006|416118004|103370009|397943006|276239002|103370009|397943006|416118004|103370009

These criteria
include|55919000
the age|424144002
of the patient,|116154003
extent|255590007
of disease|64572001
spread|410677005
,
microscopic appearance,|84496004|386548000|84496004|255412001
and
genetic features|3950001|255395001
including|55919000
DNA ploidy|88183001
and
N-myc oncogene amplification|258310009|73987007
(N-myc|258310009
regulates
microRNAs[42]
)
,
into low, intermediate,|62482003|11896004|371880002|11896004
and
high risk disease.|15508007|64572001

A recent biology study|6493001|12893009|110465008|6493001|12893009|224699009
(COG ANBL00B1
)
analyzed
2687 neuroblastoma patients|432328008|116154003|116154003
and
the spectrum
of risk assignment|30207005
was
determined
:
37%
of neuroblastoma cases|432328008|398241000|432328008|413769002|398241000|413769002
are
low risk,|62482003|30207005|371880002|30207005
18%
are
intermediate risk,|11896004|30207005
and
45%
are
high risk.|15508007

(There
is
some evidence|18669006
that
the high-|75540009|371879000
and
low-risk types|62482003|30207005|261664005|371880002|30207005|261664005
are
caused|23981006|134198009
by different mechanisms,|263735002|257544000
and
are
not merely
two|420797005
different degrees|263735002|246173007
of expression|10012005
of the same mechanism.|262126009|257544000
)
[44]

The therapies|276239002
for these different risk categories|263735002|30207005
are
very different.|260358002|263735002

With current treatments,|15240007|276239002
patients|116154003
with low|62482003|371880002
and
intermediate risk disease|11896004|30207005|64572001
have
an excellent prognosis|425405005|20481000
with cure rates
above 90%|264705001|264703008
for low risk|62482003|30207005|371880002|30207005
and
70%-90%|264705001|264703008
for intermediate risk.|11896004|30207005

In contrast,
therapy|276239002
for high-risk neuroblastoma|15508007|432328008|15508007
the past two decades|410513005|420797005
resulted|42752001|394617004
in cures only about 30%
of the time.|410669006

The addition|260364009
of antibody therapy|68498002|276239002|112133008|276239002
has
raised survival rates|260399008
for high-risk disease significantly.|15508007|64572001

In March 2009
an early analysis|264499004|272389005
of a Children's Oncology Group|410601007|3428006|261586004|410601007|3428006|160481000|410601007|3428006|389109008|160499008|3428006|261586004|160499008|3428006|160481000|160499008|3428006|389109008
(COG
)
study|110465008|224699009
with 226 high-risk patients|15508007|116154003
showed
that two years|420797005|258707000
after stem cell transplant 66%|418318001|263903005|418318001|24486003|419758009|263903005|419758009|24486003
of the group|261586004|160481000|389109008
randomized
to received ch14.18 antibody|68498002|112133008
with GM-CSF|53681007
and
IL-2|428693003
were
alive|438949009
and
disease-free|64572001|37837009
compared to only 46%
in the group|261586004|160481000|389109008
that
did
not
receive
the antibody.|68498002|112133008

The randomization
was
stopped|385654001
so
all patients enrolling|116154003
on the trial|110465008
will
receive
the antibody therapy.[50]|68498002|276239002|112133008|276239002

Chemotherapy agents|372688009|312059006
used|394850002
in combination|89780004
have
been
found|404684003
to
be
effective|255403003|254648000
against neuroblastoma.|432328008

Agents commonly|260872001
used|394850002
in induction|16404004
and
for stem cell transplant conditioning|418318001|263903005|78326006|418318001|24486003|78326006|419758009|263903005|78326006|419758009|24486003|78326006
are
platinum compounds|11996000
(cisplatin,|387318005
carboplatin,|386905002
alkylating agents|372669002
(cyclophosphamide,|387420009
ifosfamide,|386904003
melphalan,|387297002
topoisomerase II inhibitor|372537003
(etoposide,|387316009
anthracycline antibiotics|372540003
(doxorubicin|372817009
and
vinca alkaloids|61864009
(vincristine.|387126006

Some newer regimens|7147002
include|55919000
topoisomerase I inhibitors
(topotecan|372536007
and
irinotecan|372538008
in induction|16404004
which
have
been
found|404684003
to
be
effective|255403003|254648000
against recurrent disease.|58184002

Between 20%
and
50%
of high-risk cases|15508007|398241000|15508007|413769002
do
not
respond
adequately
to induction high-dose chemotherapy|16404004|261829003|416608005|16404004|261829003|367336001
and
are
progressive|255314001
or
refractory.|20646008

Relapse|263855007|255318003|58184002
after completion|255594003
of frontline therapy|276239002
is
also common.|72906007

Further treatment|46053002|276239002|46053002|416118004
is
available|103328004
in phase I|21191007|42146005|21191007|22971001
and
phase II clinical trials|21191007|110465008
that
test|269814003|272393004
new agents|7147002|260872001
and
combinations|228166004
of agents|260872001
against neuroblastoma,|432328008
but
the outcome|394617004
remains
very poor|260358002|11403006|260358002|255351007
for relapsed high-risk disease.[53]|58184002|15508007

Most long-term survivors alive today|4757001|438949009
had
low|62482003|371880002
or
intermediate risk disease|11896004|30207005|64572001
and
milder courses|255604002|288524001
of treatment|276239002|416118004
compared
to high-risk disease.|15508007|64572001

The majority
of survivors
have
long-term effects|253861007
from the treatment.|276239002|416118004

Survivors
of intermediate|11896004
and
high-risk treatment often|15508007|276239002|70232002|15508007|416118004|70232002
experience
hearing loss.|343087000|15188001

Growth reduction,|58294000|260400001|289928003
thyroid function disorders,|14304000|246464006
learning|69998004
difficulties,|371157007
and
greater risk|263768009|30207005
of secondary cancers|128462008
affect|4065008
survivors
of high-risk disease.|15508007|64572001

An estimated two|414135002|420797005
of three survivors|421291004
of childhood cancer|68433009|363346000|68433009|372087000
will
ultimately
develop
at least one chronic|276139006|421379005|90734009|263796003|421379005|90734009
and
sometimes life-threatening health problem|224130005|263775005|55607006
within 20
to 30 years|258707000
after the cancer diagnosis.[56][57][58]|363346000|439401001|363346000|372087000|439401001|372087000

Based|418836005
on a series|13039001
of 493 neuroblastoma samples,|432328008|123038009|123038009
it
has
been
reported|229059009|223458004
that overall genomic pattern,|18470003|272135003
as
tested|272393004
by array-based karyotyping,|312948004|418836005|312948004
is
a predictor
of outcome|394617004
in neuroblastoma|432328008
:
[59]

Earlier publications|264499004
categorized
neuroblastomas|432328008
into three major subtypes|421291004|255603008|260837004
based|418836005
on cytogenetic profiles
:
[60][61]

Virtual karyotyping|312948004
can
be
performed|398166005
on fresh|261013005
or
paraffin-embedded tumors to|422100001|108369006
assess
copy number|410680006|410681005
at these loci.

SNP
array
virtual karyotyping|312948004
is
preferred|225773000
for tumor samples,|258435002
including|55919000
neuroblastomas,|432328008
because
they
can
detect|260373001
copy
neutral loss
of heterozygosity|14556007
(acquired uniparental disomy|255396000
).

Copy
neutral LOH
can
be
biologically equivalent|12893009|9726003|12893009|258726008
to a deletion
and
has
been
detected|260373001
at key loci
in neuroblastoma.|432328008

ArrayCGH,
FISH,|90580008
or
conventional cytogenetics|255333006
cannot
detect|260373001
copy
neutral LOH.

Neuroblastoma|432328008
comprises
6-10%
of all childhood cancers,|68433009|363346000
and
15%
of cancer deaths|363346000|419620001|363346000|268923008|372087000|419620001|372087000|268923008
in children.|410601007|160499008

The annual mortality rate|53281000|409651001
is
10
per million children|410601007|160499008
in the 0-
to 4-year-old age group,|258381003|258707000|105436006|258381003|258707000|32864002|258381003|259039008|105436006|258381003|259039008|32864002
and
4
per million
in the 4-|260308009
to 9-year old age group.[63]|258707000|105436006|261586004|258707000|105436006|160481000|258707000|105436006|389109008|258707000|32864002|261586004|258707000|32864002|160481000|258707000|32864002|389109008|259039008|105436006|261586004|259039008|105436006|160481000|259039008|105436006|389109008|259039008|32864002|261586004|259039008|32864002|160481000|259039008|32864002|389109008

The highest incidence|75540009|371879000
is
in the first year|255216001|258707000|255216001|259039008|232714002|258707000|232714002|259039008
of life,|224130005
and
some cases|398241000|413769002
are
congenital.|6160004|255399007

The age range|424144002
is
broad,|90522003
including|55919000
older children|31114009
and
adults,|133936004
[64]
but
only 10%|50607009|420295001
of cases|398241000|413769002
occur|272120004
in people|125676002
older|70753007
than 5 years|264706000|258707000|264605009|258707000
of age.|424144002

A large European study|255509001|414152003|110465008|255509001|414152003|224699009|255509001|110465008|255509001|224699009
reported|229059009|223458004
less
than 2%|260306008
of over 4000 neuroblastoma cases|21481007|432328008|398241000|21481007|432328008|413769002|21481007|398241000|21481007|413769002
were
over 18 years old.[65]|21481007|258707000|70753007|264695004

In 1864 German physician Rudolf Virchow|7695005|309343006
was
the first to|255216001|232714002
describe
an abdominal tumor|128050000
in a child|410601007|160499008
as a "glioma".|393564001|416500007

The characteristics
of tumors|108369006
from the sympathetic nervous system|68365008|362484004
and
the adrenal medulla|38254008
were
then
noted
in 1891
by German pathologist Felix Marchand.|7695005|61207006

[67]
In 1901
the distinctive presentation|246105001
of stage 4S|261616001
in infants|418119000
(liver|10200004|181268008
but
no bone metastases|94222008
)
was
described
by William Pepper.|103582004|412066006

In 1910 James Homer Wright|25177008|373682001
understood|66216009
the tumor to|108369006
originate
from primitive neural cells,|47220008
and
named|27468005
it neuroblastoma.|432328008

He also
noted
the circular clumps|354652004|19202001
of cells|4421005
in bone marrow samples|119359002
which
are
now
termed
"Homer-Wright pseudorosettes."[68]|25177008|373682001|264697007

Recent focus|6493001|87017008|6493001|363702006
has
been
to
reduce|260400001
therapy|276239002
for low|62482003|371880002
and
intermediate risk neuroblastoma|11896004|30207005|432328008|11896004|30207005
while
maintaining survival rates|385630006
at 90%.|264705001|264703008

A study|110465008|224699009
of 467 intermediate risk patients|11896004|30207005|116154003
enrolled
in A3961
from 1997
to 2005
confirmed|59156000
the hypothesis
that therapy|276239002
could
be
successfully
reduced|260400001
for this risk group.|30207005|261586004|30207005|160481000|30207005|389109008

Those with favorable characteristics|20401003|421463005
(tumor grade|108369006|258349007|108369006|371469007
and
response
)
received four|421534005
cycles
of chemotherapy,|416608005|367336001
and
those
with unfavorable characteristics
received
eight cycles,|421825006|44180009
with three-year event free survival|421291004|258707000|272379006|37837009|421291004|259039008|272379006|37837009
and
overall survival
stable|58158008
at 90%|264705001|264703008
for the entire cohort.|255503000|260232004

Future plans|52713000|397943006
are
to
intensify
treatment|276239002|416118004
for those patients|116154003
with aberration|260980007
of 1p36
or
11q23 chromosomes|91272006
as well as
for those
who
lack|41277001
early response|264499004
to treatment.[70][71]|276239002|264699005|416118004|264699005

By contrast,
focus|87017008|363702006
the past 20 years|410513005|258707000
or
more
has
been
to
intensify
treatment|276239002|416118004
for high-risk neuroblastoma.|15508007|432328008|15508007

Chemotherapy induction variations,|416608005|16404004|40885006|367336001|16404004|40885006
timing|246512002
of surgery,|83578000
stem cell transplant regimens,|418318001|263903005|418318001|24486003|419758009|263903005|419758009|24486003
various delivery schemes|256220008|236973005|256220008|118215003
for radiation,|30821001|82107009|108290001
and
use|277889008|419385000
of monoclonal antibodies|49616005
and
retinoids to|372579009
treat|395077000
minimal residual disease|255605001|255604002
continue|255238004
to
be
examined.|64049009

Recent phase III clinical trials|6493001|21191007|257471003|110465008
with randomization
have
been
carried|288345009
out to|255529000
answer
these questions to|42425007
improve|385425000|3442003|385633008
survival
of high-risk disease|15508007|64572001
:

In addition|260364009
to these phase III studies,|21191007|257471003|110465008|21191007|257471003|224699009
some research institutions|385437003
offer|410527000
pilot treatment protocols.|308040008|276239002|258049002|308040008|416118004|258049002

For example,
St Jude's recently|6493001
finished|420604000
(2007
)
testing|272393004
a new up-front chemotherapy regimen|7147002|255532002|255549009|367336001|7147002|353734004|255549009|367336001
in 23 children|264657009|410601007|264657009|160499008
which
included|55919000
irinotecan|372538008
and
gefitinib|407100002
with 16 months|258706009
of maintenance chemotherapy|416608005|367336001
after stem cell transplant|418318001|263903005|418318001|24486003|419758009|263903005|419758009|24486003
with alternating oral 13-cis-retinoic acid|49572008|260548002|429464002
and
topotecan.|372536007

Memorial Sloan-Kettering Cancer Center|363346000|26216008|372087000|26216008
in New York|420278009
offers|410527000
treatment|276239002|416118004
that
includes|55919000
a mouse-derived monoclonal antibody,|346587004
3F8,
used|394850002
in protocols|258049002
since
the mid 1980s.|255562008

This antibody|68498002|112133008
is
used|394850002
for treating minimal residual disease|28995006|255605001|28995006|255604002
or
consolidation|9656002
instead of stem cell transplant.|418318001|263903005|418318001|24486003|419758009|263903005|419758009|24486003

A new pilot protocol COG-ANBL09P1|272414007|7147002|308040008|258049002|410601007|3428006|272414007|7147002|308040008|258049002|160499008|3428006
available|103328004
for newly
diagnosed|439401001
(high-risk|15508007
)
children at several Children's Oncology Group (COG) centers|410601007|3428006|261586004|26216008|410601007|3428006|160481000|26216008|410601007|3428006|389109008|26216008|160499008|3428006|261586004|26216008|160499008|3428006|160481000|26216008|160499008|3428006|389109008|26216008
will
offer|410527000
MIBG radiotherapy|395786000|419815003|395786000|108290001
and
chemotherapy|416608005|367336001
for the transplant regimen.[91]|263903005|24486003

Some children|410601007|160499008
(particularly
in high-risk cases|15508007|398241000|15508007|413769002
)
do
not
respond
completely
to frontline treatment|276239002|416118004
(
with a complete response|103338009
or
very good partial response|260358002|20572008|103337004
)
and
are
labeled
refractory.|20646008

These children|410601007|160499008
are
removed|127485006
from the frontline therapy|276239002
(clinical trial|110465008
)
and
are
eligible
for clinical trials|110465008
using|260676000
new therapies.|7147002|276239002

Many high-risk children|15508007|410601007|15508007|160499008
have
a good response|20572008
to frontline therapy|276239002
and
achieve
a remission,|277022003
but
later
the disease recurs|64572001|246455001
(relapse|263855007|255318003|58184002
).

These children|410601007|160499008
are
also eligible
for new therapies|7147002|276239002
being
tested|272393004
in clinical trials.|110465008

Chemotherapy|416608005|367336001
with topotecan|372536007
and
cyclophosphamide|387420009
is
frequently|70232002
used|394850002
in refractory setting|20646008
and
after relapse.|263855007|255318003|58184002

A randomized study|110465008|224699009
(2004
)
with 119 patients|116154003
(comparing topotecan|372536007
alone|105529008
to topotecan|372536007
and
cyclophosphamide|387420009
)
revealed|263857004
a 31% complete|264664006|255594003
or
partial response rate|103337004
with two-year progression-free survival|420797005|258707000|246453008|37837009|420797005|258707000|246450006|37837009|420797005|259039008|246453008|37837009|420797005|259039008|246450006|37837009
at 36%
in the topotecan|372536007
and
cyclophosphamide group.|387420009|261586004|387420009|160481000|387420009|389109008

Irinotecan|372538008
(intravenous|255560000
or
oral|260548002
)
and
oral temozolomide|260548002|387009002
are
also
used|394850002
in refractory|20646008
and
recurrent neuroblastoma.[93][94]|255227004|432328008|255227004

Many phase I|260396001|21191007|42146005|260396001|21191007|22971001
and
phase II trials|21191007|110465008
are
currently|15240007
testing|272393004
new agents|7147002|260872001
against neuroblastoma|432328008
in children|410601007|160499008
who
have
relapsed|255318003
or
are
resistant|30714006
to initial therapy.|884001|276239002|232714002|276239002

Investigators
are
currently|15240007
studying|110465008|224699009
new agents,|7147002|260872001
alone|105529008
and
in new combinations,|7147002|228166004
using|260676000
small molecule|255507004|290005005
targeted
therapy,|276239002
131-I MIBG radiation therapy,|42146005|395786000|108290001|22971001|395786000|108290001
angiogenesis agents,|260872001
new monoclonal antibodies,|7147002|49616005
vaccines,|398827000
oncolytic viruses,|49872002
as well as
new myeloablative regimens.|7147002

A group|261586004|160481000|389109008
of 16 children?s hospitals|82242000
in the United States|223688001
known|36692007
as the New Advances in Neuroblastoma Therapy (NANT) consortium|7147002|86005002|432328008|276239002|7147002|86005002|276239002
coordinates|162258009
the I-131 MIBG radiation therapy trials.|404836005|395786000|108290001|110465008

The NANT consortium also
offers|410527000
trials|110465008
using|260676000
an oral powder formulation|385041009
of fenretinide,
intravenous fenretinide,|255560000
bisphosphonate|372907000
(Zometa
)
with other agents,|74964007|260872001
and
combining I-131 MIBG|89780004|404836005|395786000|20909006|404836005|395786000
with the inhibitor vorinostat.[95]|61511001|422505001

Other research study groups|74964007|110465008|261586004|74964007|110465008|160481000|74964007|224699009|261586004|74964007|224699009|160481000
such as The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) also|432328008|443333004|443333004
conduct|844005
clinical trials to|110465008
treat|395077000
relapse neuroblastoma.|263855007|432328008|263855007|255318003|432328008|255318003|58184002|432328008|58184002

Institutions|385437003
in Europe|223502009
are
studying|110465008|224699009
novel therapies to|7147002|276239002
treat|395077000
relapse,|263855007|255318003|58184002
including|55919000
haploidentical stem cell transplant.|418318001|263903005|418318001|24486003|419758009|263903005|419758009|24486003

Many hospitals|260396001
conduct|844005
their own institutional studies|257622000|110465008|257622000|224699009|385437003|110465008|385437003|224699009
as well.|20572008

The protein p53|88878007
is
believed to
play|300776002
a role
in the development|278923009
of resistance|30714006
to chemotherapy.|416608005|367336001

A November 2009 study|110465008|224699009
in mice|447612001|447482001
shows
that
activating
the tumor suppressor p53|77864004
with a new drug,|7147002|410942007
nutlin-3,
may
slow tumor growth.|419443000|108369006

In this study,|110465008|224699009
physician Tom Van Maerken|309343006|224832000
of Ghent University Hospital|224871002|224871002|285201006
in Belgium|223660007
and
his colleagues
used|394850002
nutlin-3 to
neutralize
MDM2,
a protein|88878007
that
binds|257768005
to the p53 protein|88878007
and
obstructs|263821009
p53?s ability to|371150009
trigger|410658008
programmed cell death.|20663007

Earlier studies|264499004|110465008|264499004|224699009
have
shown
that nutlin-3
can
specifically
prevent
MDM2
from disabling p53.

[U.S.|223688001

Representative]
(/wiki/U.S._Representative
)
Chet Edwards
of Waco,
Texas,|421662006
successfully introduced legislation to|127487003
earmark
$150 million
toward a cure
for neuroblastoma|432328008
and
other cancers.|74964007|363346000

The measure|246445000|272391002
was
signed|72670004
into law
in July 2008
by [U.S.|223688001

President]
(/wiki/U.S._President
)
[George W.

Bush]|112591004
(/wiki/George_W._Bush|112591004
).

Edwards
was
inspired|14910006
in the endeavor
by the illness|39104002
and
subsequent death|255260001|419620001|255260001|268923008
of Erin Channing Buenger
(1997?2009
)
of Bryan,
daughter|66089001
of one|421379005
of his constituents,|312297002
[Walter L.

Buenger]
(/wiki/Walter_L._Buenger
)
,
head|69536005|302548004
of the history department|392521001
at Texas A&M University.[100]|421662006|224871002

M
:
CNS

anat(n/s/m/p/4/e/b/d/c/
a/f/l/g/phys/devp

noco
(m/d/e/h/v/s/cong/tumr,
sysi/epon,
injr

proc,
drug|410942007
(N1A/2AB/C/3/4/7A/B/C/D|277672002

M
:
PNS|3058005

anat(h/r/t/c/b/l/s/a/phys
(r/devp/prot/nttr/nttm/ntrp|24028007|304383000

noco/auto/cong/tumr,
sysi/epon,
injr

proc,
drug|410942007
(N1B|277674001

M
:
END|261782000|422117008

anat/phys/devp/horm

noco
(d/cong/tumr,|876000
sysi/epon

proc,
drug|410942007
(A10/H1/H2/H3/H5

